UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Annals of oncology, 2019-08, Vol.30 (8), p.1321-1328

2019

Volltextzugriff (PDF)

Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016

Annals of oncology, 2018-12, Vol.29 (12), p.2288-2295

2018

Volltextzugriff (PDF)

Malignant pleural mesothelioma: new guidelines make us stronger for defeating this disease

Annals of oncology, 2022-02, Vol.33 (2), p.123-125

2022

Volltextzugriff (PDF)

Consensus clustering methodology to improve molecular stratification of non-small cell lung cancer

Scientific reports, 2023-05, Vol.13 (1), p.7759-7759, Article 7759

2023

Volltextzugriff (PDF)

PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade

British journal of cancer, 2023-10, Vol.129 (9), p.1409-1416

2023

Volltextzugriff (PDF)

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

Scientific reports, 2022-05, Vol.12 (1), p.8342-8342, Article 8342

2022

Volltextzugriff (PDF)

Addressing the unmet need in lung cancer: The potential of immuno-oncology

Cancer treatment reviews, 2015-06, Vol.41 (6), p.465-475

2015

Volltextzugriff (PDF)

Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis

Annals of oncology, 2017-10, Vol.28, p.vi90-vi90

2017

Volltextzugriff (PDF)

MS13.06 Role of Second Line Chemotherapy and New Target Treatment in Recurrent Mesothelioma

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S182-S183

2019

Volltextzugriff (PDF)

P2.04-03 Perceptions and Knowledge of Electronic Smoking Devices among Patients with Solid Tumors and their Care-Givers

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S132-S133

2022

Volltextzugriff (PDF)

2266P IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort

Annals of oncology, 2023-10, Vol.34, p.S1164-S1164

2023

Volltextzugriff (PDF)

1510TiP Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)

Annals of oncology, 2023-10, Vol.34, p.S850-S850

2023

Volltextzugriff (PDF)

1355P Clinical trial enrollment among lung cancer patients: A real-world multicenter analysis

Annals of oncology, 2022-09, Vol.33, p.S1158

2022

Volltextzugriff (PDF)

1640TiP PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC)

Annals of oncology, 2022-09, Vol.33, p.S1291

2022

Volltextzugriff (PDF)

1676P Nutritional assessment in the era of targeted therapies in advanced non-small cell lung cancer (aNSCLC) oncogene-addicted patients

Annals of oncology, 2021-09, Vol.32, p.S1177-S1177

2021

Volltextzugriff (PDF)

1811P Molecular characterization of epidermal growth factor receptor-mutated (EGFR-m) non-small cell lung cancer (NSCLC) undergoing histological transformation

Annals of oncology, 2021-09, Vol.32, p.S1230-S1231

2021

Volltextzugriff (PDF)

1368TiP EPROPA: The European program for routine testing of patients with advanced lung cancer

Annals of oncology, 2021-09, Vol.32, p.S1037-S1038

2021

Volltextzugriff (PDF)

140P Prognostic and predictive value of co-mutational profile in advanced EGFR positive NSCLC patients treated with TKIs

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S773-S773

2021

Volltextzugriff (PDF)

OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S53-S54

2023

Volltextzugriff (PDF)

P59.20 Natural History of KRAS Mutant Non-Small-Cell Lung Cancer in the Immunotherapy Era: A Single-Centre Retrospective Study

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1156-S1157

2021

Volltextzugriff (PDF)

MA12.07 Oncological Procedures and Risk Assessment of COVID-19 in Thoracic Cancer Patients: A Picture From an Italian Cancer Center

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S923-S924

2021

Volltextzugriff (PDF)

1783P Multi-parametric T cells profiling in broncho-alveolar lavage fluid (BAL) and blood from advanced lung cancer patients

Annals of oncology, 2021-09, Vol.32, p.S1219-S1220

2021

Volltextzugriff (PDF)

Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis

Annals of oncology, 2017-09, Vol.28, p.v548-v548

2017

Volltextzugriff (PDF)

EP16.03-011 The European Program for ROutine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S590

2022

Volltextzugriff (PDF)

P1.28-09 Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S292-S293

2023

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(49)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016

Malignant pleural mesothelioma: new guidelines make us stronger for defeating this disease

Consensus clustering methodology to improve molecular stratification of non-small cell lung cancer

PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

Addressing the unmet need in lung cancer: The potential of immuno-oncology

Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis

MS13.06 Role of Second Line Chemotherapy and New Target Treatment in Recurrent Mesothelioma

P2.04-03 Perceptions and Knowledge of Electronic Smoking Devices among Patients with Solid Tumors and their Care-Givers

2266P IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort

1510TiP Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)

1355P Clinical trial enrollment among lung cancer patients: A real-world multicenter analysis

1640TiP PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC)

1676P Nutritional assessment in the era of targeted therapies in advanced non-small cell lung cancer (aNSCLC) oncogene-addicted patients

1811P Molecular characterization of epidermal growth factor receptor-mutated (EGFR-m) non-small cell lung cancer (NSCLC) undergoing histological transformation

1368TiP EPROPA: The European program for routine testing of patients with advanced lung cancer

140P Prognostic and predictive value of co-mutational profile in advanced EGFR positive NSCLC patients treated with TKIs

OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01

P59.20 Natural History of KRAS Mutant Non-Small-Cell Lung Cancer in the Immunotherapy Era: A Single-Centre Retrospective Study

MA12.07 Oncological Procedures and Risk Assessment of COVID-19 in Thoracic Cancer Patients: A Picture From an Italian Cancer Center

1783P Multi-parametric T cells profiling in broncho-alveolar lavage fluid (BAL) and blood from advanced lung cancer patients

Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis

EP16.03-011 The European Program for ROutine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity

P1.28-09 Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel

Suchergebnisse filtern